Comprehensive Genomic Profiling

July 19th 2022

As the number of known cancer targets and precision therapies increases, implementing whole-genome sequencing (WGS) into regular clinical practice may benefit patients with metastatic cancer.

July 16th 2022

While comprehensive genetic profiling has the potential to change the course of certain patients’ cancers, a recent survey found that patients often have difficulty understanding results and their implications.

July 7th 2022

Successful comprehensive genomic profiling of tissue samples among patients with lung cancer was more likely to occur when samples were extracted via resections vs fluid cytology, biopsy, or fine-needle aspirations.

July 1st 2022

Patients with iCCA, particularly those whose disease progresses following first-line chemotherapy, have limited overall treatment options. Data presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting show that patients may soon have a new agent to fight this rare cancer in futibatinib (Taiho Oncology), an FGFR inhibitor.